Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SCPX

Scorpius Holdings Inc

Dec 20 • 04:00PM ET

0.3396

Dollar change -0.0421
Percentage change -11.03	%

Healthcare • Biotechnology • USA • AMEX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-101.01	Insider Own	7.58%	Shs Outstand	4.87M	Perf Week	13.16%
Market Cap	1.47M	Forward P/E	-	EPS next Y	-2.91	Insider Trans	0.00%	Shs Float	4.50M	Perf Month	-48.93%
Income	-28.81M	PEG	-	EPS next Q	-	Inst Own	16.03%	Short Float	1.74%	Perf Quarter	-56.50%
Sales	10.04M	P/S	0.15	EPS this Y	97.91%	Inst Trans	-	Short Ratio	0.32	Perf Half Y	-98.37%
Book/sh	8.12	P/B	0.04	EPS next Y	59.92%	ROA	-50.94%	Short Interest	0.08M	Perf Year	-99.47%
Cash/sh	1.11	P/C	0.31	EPS next 5Y	-	ROE	-91.23%	52W Range	0.28 - 110.00	Perf YTD	-99.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.72%	ROI	-71.76%	52W High	-99.69%	Beta	-0.27
Dividend TTM	-	Quick Ratio	0.60	Sales past 5Y	325.62%	Gross Margin	-9.53%	52W Low	22.33%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	0.62	EPS Y/Y TTM	74.79%	Oper. Margin	-311.72%	RSI (14)	31.96	Volatility	31.04% 18.55%
Employees	84	Debt/Eq	0.52	Sales Y/Y TTM	351.08%	Profit Margin	-286.88%	Recom	1.00	Target Price	5.00
Option/Short	No / Yes	LT Debt/Eq	0.40	EPS Q/Q	98.58%	Payout	-	Rel Volume	2.73	Prev Close	0.38
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	27.55%	Earnings	Nov 14 AMC	Avg Volume	245.81K	Price	0.34
SMA20	-23.68%	SMA50	-46.03%	SMA200	-97.50%	Trades		Volume	672,048	Change	-11.03%

Nov-19-24 07:30AM	Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model (GlobeNewswire)
Nov-14-24 04:15PM	Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability (GlobeNewswire) -8.61%
Nov-04-24 07:30AM	Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement (GlobeNewswire)
Oct-31-24 07:30AM	Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually (GlobeNewswire) -5.26%
Oct-22-24 03:58PM	Scorpius Partners with Biotech Firm to Boost U.S. Biomanufacturing Capabilities (GuruFocus.com)
08:00AM	Loading…
08:00AM	Scorpius Holdings Announces Partnership with U.S. Biotech Company (GlobeNewswire)
Oct-02-24 08:00AM	Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats (GlobeNewswire)
Sep-30-24 08:00AM	Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities (GlobeNewswire)
Sep-12-24 08:00AM	Scorpius Holdings Commends the U.S. House of Representatives' Passage of the BIOSECURE Act (GlobeNewswire)
Sep-09-24 08:30AM	Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA (GlobeNewswire)
Aug-26-24 08:00AM	Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow (GlobeNewswire)
Aug-20-24 09:15AM	Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024 (GlobeNewswire) -10.52%
Aug-19-24 01:08PM	Scorpius Holdings, Inc. Announces Closing of Public Offering (GlobeNewswire) -12.84%
Aug-16-24 09:50AM	Scorpius Holdings, Inc. Announces Pricing of Public Offering (GlobeNewswire)
Aug-09-24 03:38PM	Scorpius Holdings, Inc. Provides Update on its Previously Announced Public Offering (GlobeNewswire)
08:45AM	Loading…
Aug-06-24 08:45AM	Scorpius Holdings Weighted-Average Pipeline Surpasses $100 Million in Business Develop Opportunities Across Both Manufacturing Client and Government Sectors (ACCESSWIRE) +19.27%
08:16AM	Exclusive: Healthcare Service Provider Scorpius Surpasses $100M In Business Opportunities, Eyes Revenue Boost (Benzinga)

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCPX

Scorpius Holdings Inc

Upgrade your FINVIZ experience